Citius Oncology Files Prospectus Supplement: Board Expansion, Q3 Losses, Going Concern Warning
CTOR sits 71% above its 52-week low of $0.491 on elevated volume (2.9× avg).
Summary
Citius Oncology filed a prospectus supplement incorporating an 8-K and 10-Q. The 10-Q shows Q3 revenue of $1.5M, a net loss of $8.9M, a going concern warning, and Nasdaq delisting risk. The board expanded to nine members with the appointment of Jonathan Peri.
Key Events · Financing and Capital Events · CTOR
-
Board Expansion
Jonathan Peri, Ph.D., J.D. appointed as independent Class I director effective August 10, 2026, expanding the board to nine members.
-
Q3 Financial Results
Revenue of $1.5M for the quarter and $7.1M for nine months; net loss of $8.9M for the quarter and $41.1M for nine months.
-
Going Concern Warning
Cash of $16.6M at June 30, 2026; runway expected only through November 2026, raising substantial doubt about ability to continue as a going concern.
-
Nasdaq Delisting Risk
Non-compliance with minimum bid price rule; compliance deadline October 19, 2026.
Analysis · CTOR · Life Sciences
Citius Oncology's prospectus supplement incorporates an 8-K announcing the appointment of Jonathan Peri to the board and a 10-Q revealing deepening losses, a going concern warning, and Nasdaq delisting risk. The company's cash runway extends only to November 2026, and it faces a $19.7M CMO termination fee. This filing is critical for investors assessing the company's survival prospects.
At the time of this filing, CTOR was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.6M. The 52-week trading range was $0.49 to $2.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.